COMPAZINE Drug Patent Profile
✉ Email this page to a colleague
When do Compazine patents expire, and what generic alternatives are available?
Compazine is a drug marketed by Glaxosmithkline and is included in seven NDAs.
The generic ingredient in COMPAZINE is prochlorperazine. There are twenty-one drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the prochlorperazine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Compazine
A generic version of COMPAZINE was approved as prochlorperazine by COSETTE on November 24th, 1993.
Summary for COMPAZINE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 7 |
Raw Ingredient (Bulk) Api Vendors: | 57 |
Clinical Trials: | 19 |
Patent Applications: | 4,172 |
Formulation / Manufacturing: | see details |
DailyMed Link: | COMPAZINE at DailyMed |
Recent Clinical Trials for COMPAZINE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Michigan Rogel Cancer Center | Phase 3 |
Indiana University | Phase 2 |
Kyowa Kirin | Phase 2 |